drugset
drugset / Trial / NCT07542847

A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women

NCT07542847 ↗

Phase 1 Completed 24 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this trial is to assess the potential for cytochrome P450 (CYP)-mediated drug-drug interactions (DDIs) with OPC-167832. The study is conducted in 2 parts: Part 1 assesses the potential effect of the CYP3A inhibitor itraconazole on the metabolism of OPC-167832 and Part 2 assesses the potential effect of the CYP3A inducer carbamazepine on the metabolism of OPC-167832 in healthy adult participants.

Timeline

Start
2022-09-19
Primary completion
2022-11-18
Completion
2022-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule — Oral
Subject Itraconazole Small molecule — Oral
Subject Quabodepistat Small molecule — Oral

Indications

No indication recorded.